Achieve Life Sciences, Inc. announced its financial results for Q4 and the year-end 2024, while reaffirming plans to submit a new drug application (NDA) for cytisinicline, a treatment for nicotine ...

Achieve Life Sciences, Inc. initiated an open-label ORCA-OL trial using cytisinicline for smoking cessation; the Efficacy of the drug already established in several prior studies. Alignment with FDA ...

CEO Rick Stewart stated that "Achieve is on track to submit the NDA for cytisinicline next month." He emphasized that "all internal resources are now focused on a successful NDA submission, acceptance ...

Over 300 Participants Have Completed Cumulative Six Months of Cytisinicline Treatment in the ORCA-OL Trial, Completing the Long-Term Exposure Requirement for NDA Submission ORCA-OL Long-Term Exposure ...

SEATTLE and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the global development and ...

CHICAGO--(BUSINESS WIRE)--The Planet Group ("Planet"), a leading provider of outsourced human capital and consulting solutions and a portfolio company of MidOcean Partners, announced today that it has ...